Skip to main content
SpringerLink
Log in

The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours

  • comment
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Cancer Treat Res. 2015;88:154–9.

    Google Scholar 

  2. Bedekovics J, Beke L, Mokanszki A, et al. Programmed death-ligand 1 (PD-L1) expression in Thymic epithelial tumors. Appl Immunohistochem Mol Morphol. 2020;28:1–9.

    Article  CAS  Google Scholar 

  3. Weissferdt A, Fujimoto J, Kalhor N, et al. Expression of PD‑1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017;30:826–33.

    Article  CAS  Google Scholar 

  4. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19:347–55.

    Article  CAS  Google Scholar 

  5. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed Thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37:2162–70.

    Article  CAS  Google Scholar 

  6. Rajan A, Heery CR, Thomas A, et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer. 2019;7:269.

    Article  Google Scholar 

  7. Shen L, Chen H, Wei Q. Immune-therapy-related toxicity events and dramatic remission after a single dose of pembrolizumab treatment in metastatic thymoma: a case report. Front Immunol. 2021;12:621858.

    Article  CAS  Google Scholar 

  8. Konstantina T, Konstantinos R, Anastasios K, et al. Fatal adverse events in two thymoma patients treated with anti-PD‑1 immune check point inhibitor and literature review. Cancer Treat Res. 2019;135:29–32.

    Google Scholar 

  9. Katsuya Y, Horinouchi H, Seto T, et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer. 2019;113:78–86.

    Article  CAS  Google Scholar 

  10. Merveilleux du Vignaux C, Dansin E, Mhanna L, et al. Systemic therapy in advanced Thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762–70.

    Article  Google Scholar 

  11. Zander T, Aebi S, Rast AC, et al. Response to pembrolizumab in a patient with relapsing Thymoma. J Thorac Oncol. 2016;11:e147–e9.

    Article  Google Scholar 

  12. Chen Q, Huang DS, Zhang LW, et al. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. Clin Toxicol. 2018;56:667–71.

    Article  CAS  Google Scholar 

  13. Girard N, Merveilleux du Vignaux C. Systemic treatment for thymic malignancies. Curr Opin Oncol. 2017;29:112–7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany

    Wolfgang Jungraithmayr MD PhD

Authors
  1. Wolfgang Jungraithmayr MD PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Jungraithmayr MD PhD.

Ethics declarations

Conflict of interest

W. Jungraithmayr declares that he has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jungraithmayr, W. The double-edged sword of immune checkpoint inhibition in advanced staged thymic epithelial tumours. memo 14, 373–375 (2021). https://doi.org/10.1007/s12254-021-00737-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-021-00737-x

Search

Navigation